unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma with PD-L1 expression. In esophageal cancer, the agent is also approved by regulatory agencies in combination with platinum- and ...

Bart Frazzitta was told he had a 5% chance of surviving esophageal cancer. Twenty-five years later, he's still here and ...

The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Phase 3 trial showed Keytruda-Lenvima improves progression-free survival and response rates in HER2-negative ... is a rare type of cancer that occurs in the esophagus, the passageway that ...

Adding evorpacept to treatment with trastuzumab, ramucirumab, and paclitaxel may improve outcomes in HER2-positive gastric/GEJ cancer.

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but missing out on overall survival.

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve statistical significance for overall survival in patients with advanced ...

The LEAP-015 study is evaluating Merck's Keytruda and Eisai's Lenvima plus chemotherapy in certain types of gastroesophageal ...

Among patients with advanced gastric and GEJ cancer, or esophageal adenocarcinoma ... Patients had no known HER2 positivity and an ECOG performance status of 0 or 1. Study enrollment occurred at 175 ...